3 Pages
English

Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease

Gain access to the library to view online
Learn more

Description

Frost & Sullivan Recognizes Sanovas for its Path-Breaking Innovation in the Treatment of Pulmonary Disease PR Newswire MOUNTAIN VIEW, California, June 12, 2012 - The company's unique Vas Zeppelin catheter-based microsurgery technology platform combines the strengths of various treatment approaches while minimizing associated risks MOUNTAIN VIEW, California, June 12, 2012 /PRNewswire/ -- Based on its recent analysis of the pulmonary disease treatment market, Frost & Sullivan recognizes Sanovas, Inc. with the 2012 North American Frost & Sullivan Award for New Product Innovation. Sanovas's pioneering Vas Zeppelin microsurgery technology platform represents a major leap forward in the tools available to diagnose and treat lung cancer and other airway obstructions. The increasing incidence of pulmonary disease has already reached epidemic proportions. Due to the lack of effective treatment and curative solutions, the vast majority of treatment costs go toward palliative care services that provide no chance of recovery and minimal quality-of-life enhancement for patients. The lack of effective options for this highly under-served patient population underscores the need for novel and innovative approaches. "Given the unique anatomical structure of the lungs, most existing treatment options including surgery, chemotherapy, and radiation come with major trade- offs," says Venkat Rajan, Frost & Sullivan's industry manager for advanced medical technologies.

Subjects

Informations

Published by
Reads 64
Language English
Frost & Sullivan Recognizes Sanovas for its
Path-Breaking Innovation in the Treatment of
Pulmonary Disease
PR Newswire
MOUNTAIN VIEW, California, June 12, 2012
- The company's unique Vas Zeppelin catheter-based microsurgery technology
platform combines the strengths of various treatment approaches while
minimizing associated risks
MOUNTAIN VIEW, California
,
June 12, 2012
/PRNewswire/ -- Based on its recent
analysis of the pulmonary disease treatment market, Frost & Sullivan
recognizes Sanovas, Inc. with the 2012 North American Frost & Sullivan Award
for New Product Innovation. Sanovas's pioneering Vas Zeppelin microsurgery
technology platform represents a major leap forward in the tools available to
diagnose and treat lung cancer and other airway obstructions.
The increasing incidence of pulmonary disease has already reached epidemic
proportions. Due to the lack of effective treatment and curative solutions, the
vast majority of treatment costs go toward palliative care services that provide
no chance of recovery and minimal quality-of-life enhancement for patients.
The lack of effective options for this highly under-served patient population
underscores the need for novel and innovative approaches.
"Given the unique anatomical structure of the lungs, most existing treatment
options including surgery, chemotherapy, and radiation come with major trade-
offs," says Venkat Rajan, Frost & Sullivan's industry manager for advanced
medical technologies. "Sanovas is developing tools that are re-imagining what
is possible in a disease where major advances in care over the past decade
have been nominal."
The Vas Zeppelin catheter-based microsurgery platform is a feat in medical
device convergence unlike any other. Typically, a convergent medical device
indicates a two-in-one drug-device combination, diagnostic-treatment tool, or
imaging-intervention product of some variety. However, Sanovas has
developed a platform technology that for the first time offers physicians a
flexible collection of real-time imaging, access, resection, diagnostics, and drug
delivery tools in one therapy enabling system.
"The Vas Zeppelin microsurgical technology platform could be the
breakthrough that significantly alters the existing paradigm," opines Venkat.
"Early detection and intervention could be the key to providing patients
diagnosed with lung cancer a more optimistic prognosis."
Due to its optimal profile and multifaceted construct, the Vas Zeppelin platform
can conceivably address pathology found in small diameter anatomy below 3
millimeters. Altogether, Sanovas has provided an all-in-one solution at a scale
and at dimensions that may very well enable early intervention in small
diameter anatomies that are not currently accessible. The platform combines
the strength of various treatment approaches and minimizes the associated
risks of venturing into the lungs.
The Vas Zeppelin platform's on-board imaging capabilities provide